immunolabelling should be adopted when using this antibody. This is because optimal immunolabelling is determined not only by the features of the antibody, but also by the quality and preservation of the tissue under study. In our experience, when using tissue that has been recovered and processed according to recently adopted Standard Operating Procedures, such as those used within the JDRF Network for Pancreatic Organ Donors with Diabetes (nPOD) programme [3] , then a high dilution (e.g. 1:2,000) of clone 5D8/1 can be employed to achieve optimal, selective immunolabelling of viral antigen. However, for those historical collections in which tissue samples were recovered at autopsy and then fixed according to nonstandardised methods [4] , the use of high dilutions of clone 5D8/1 is not appropriate. Indeed, in such samples, a dilution of 1:2,000 of clone 5D8/1 fails to detect immunopositivity in proven Coxsackievirus-infected tissue samples, even after vigorous antigen retrieval. By contrast, a dilution of 1:500 stains the Coxsackievirus-infected tissue samples very clearly, whereas controls remain immunonegative. Thus, it is not appropriate to attempt to define a single labelling protocol or antibody dilution. Rather, it is more important to ensure that appropriate optimisation is achieved for each set of tissue samples independently (including by the use of validated positive and negative controls). This has always been our approach and allows us to retain full confidence in the immunolabelling we reported previously with clone 5D8/1 in human pancreas (for example, see [4] ).
A second important factor concerns the chemical configuration of the antibody itself. In various studies cited in their letter, Hansson et al note that high (and, by implication, suboptimal) concentrations of antibody were used. However, it is important to emphasise that in some of these experiments, the antiserum had been chemically modified prior to its use (for example, by biotinylation [5, 6] ) and that the dilutions were then dictated by the modifications employed. As such, they illustrate, again, that it is not feasible to define a single dilution or a unique set of incubation conditions that apply in all circumstances.
In drawing more general conclusions about the validity and outcomes of immunohistochemistry, Hansson et al [1] also make reference to the immunolabelling achieved with two further antisera used in our recent study: those raised against ATP5B and creatine kinase B (CKB). They argue that the labelling achieved with these reagents may have been suboptimal because we did not detect 'the general expression of these proteins within all cells in the human pancreas' [1] . This would be an important conclusion if the underlying premise was true. Unfortunately, it is not. In contrast to their notion that CKB may be both mitochondrial [7] and ubiquitously expressed [1] this enzyme is known to adopt a predominantly cytosolic localisation within cells and to display a restricted tissue distribution [8] . Importantly, while we can readily detect CKB in human heart and stomach by immunohistochemistry, it is not present in the majority of cells of the pancreas. This concurs fully with data obtained in the mouse [8] and with the distribution of CKB defined in the Human Protein Atlas (www.proteinatlas.org; accessed 7 January 2014) using two independent antibodies. ATP5B, on the other hand, is a mitochondrial component expressed in a wider range of cells and, accordingly, we show ubiquitous immunolabelling of this protein within both the endocrine and exocrine compartments in sections of pancreas. Thus, we consider that our ability to detect the expression of CKB and ATP5B according to their expected cellular and tissue distribution bears testimony to the rigour and validity of the optimisation procedures employed.
Finally, it is important to comment on an additional finding reported in our previous work [4] : that immunopositive labelling was detected when probing the pancreases of either normal adults (13% of cases) or patients with type 2 diabetes (40% of cases) with clone 5D8/1. A critical point is that the proportion of immunopositive islet cells was extremely low in both of these populations. This might be taken to imply that non-viral antigens were detected more readily by clone 5D8/1 in the islets of adults than in children. However, since enteroviruses circulate widely in the population and have a relatively high degree of tropism for the islet beta cells, an alternative explanation is that they can establish (perhaps persistent?) infections that are then detected more frequently in the pancreases of individuals at increasing age. Hence, we suspect that it is not the presence or absence of virus per se within a beta cell that is of most significance for the onset of diabetes (either type 1 or type 2). Rather, it may be the response of the cell to an ongoing viral infection that matters. Conceivably, for type 1 diabetes, it is those children who respond most vigorously to an early beta cell enteroviral infection (including by secretion of interferons and subsequent hyper-expression of islet class I MHC) who are at greatest risk of triggering islet autoimmunity, while those who respond minimally (or not at all) are relatively protected. By contrast, in adults predisposed to type 2 diabetes, the presence of an enteroviral infection within some beta cells may exacerbate an already defective insulin secretory response in these cells. In either case, we would not wish to dismiss the detection of immunopositivity simply as evidence of some random loss of specificity of the immunolabelling technique.
We conclude by emphasising one further point. Namely, that we concur fully with Hansson et al [1] in calling for additional studies to verify the presence of enterovirus in pancreas. We accept that it is not sufficient to rely solely on a single immunohistochemical reagent when reaching conclusions about the molecular target. Additional confirmation is required. This may come in various forms but, for enteroviral infections of beta cells in human type 1 diabetes, the isolation and characterisation of viral RNA remains a key priority. Duality of interest HH is a minor (<5%) shareholder and member of the board of Vactech, which develops vaccines against picornaviruses. All other authors declare that there is no duality of interest associated with this manuscript.
